All of the articles that I've read requires the drug to be FDA-approved BEFORE they repurpose it for another disease...therefore, we have to wait until after the FDA approves our NDA for Rett.
However, once A2-73 is approved, Anavex will shift into high gear and start conducting P3 trials for each disease in our pipeline. This will be exciting because Anavex can become the go-to drug for neurological diseases. But we've got to get Rett over the finished line first. God willing.